Company profile: Cullgen
1.1 - Company Overview
Company description
- Provider of drug discovery services leveraging its uSMITE platform to develop targeted protein degraders using novel E3 ligands for diseases lacking effective therapies, including cancer, inflammation, autoimmune, and neurodegenerative disorders; pipeline includes CG001419, an orally bioavailable pan-TRK degrader in phase I/II clinical trial for solid tumors.
Products and services
- Targeted Protein Degraders: Engineers small-molecule degraders that expand drug design beyond functional site inhibition, targeting cancer, inflammation, autoimmune, and neurodegenerative diseases through small molecule-induced protein degradation
- CG001419: Orally bioavailable pan-TRK degrader under Phase I/II clinical trial for solid tumors, representing Cullgen’s advancement in targeted protein degradation
- USMITE™ platform: Proprietary platform utilizes novel E3 ligands to develop targeted protein degraders aimed at treating diseases with no effective therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cullgen
SciFluor
HQ: United States
Website
- Description: Provider of fluorination technologies that improve drug properties, such as metabolic stability and potency.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SciFluor company profile →
Kinarus
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies targeting stress-related inflammatory processes. Develops KIN001, a pamapimod/pioglitazone combination with anti-inflammatory, anti-fibrotic, and antiviral activities, in Phase 2 trials for hospitalized COVID-19 (acute and long-term), wet AMD (reducing anti-VEGF injection frequency), and IPF (reducing lung fibrosis).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinarus company profile →
Exzell Pharma
HQ: Canada
Website
- Description: Provider of medicines, healthcare and biopharma-based products, including EsopH OTC therapy for GERD that relieves heartburn and can be used with PPI prescriptions; Swiss Natural vitamins, supplements and minerals from natural sources; Salinex nasal spray to hydrate and cleanse; PediaVit vitamins and iron for infants and children; Koena multi-strain probiotics; and Ozonol ointment for scrapes, minor burns, and skin irritations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exzell Pharma company profile →
InnoPharma
HQ: United States
Website
- Description: Provider of niche-generic, specialty pharmaceutical and bio-pharmaceutical product development, operating as a privately held pharmaceutical R&D company founded in 2005 and based in Piscataway, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InnoPharma company profile →
Herantis Pharma
HQ: Finland
Website
- Description: Provider of pharmaceutical therapies targeting unmet clinical needs, including HER-096, a small synthetic peptidomimetic based on the CDNF protein's active site for treating Parkinson’s disease, designed for subcutaneous administration and demonstrating good safety, tolerability, and efficient blood-brain barrier penetration in Phase 1a clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Herantis Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cullgen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cullgen
2.2 - Growth funds investing in similar companies to Cullgen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cullgen
4.2 - Public trading comparable groups for Cullgen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →